about
Reversal of high dietary fructose-induced PPARalpha suppression by oral administration of lipoxygenase/cyclooxygenase inhibitorsWeight control and prevention of metabolic syndrome by green tea.Diagnosis and management of the metabolic syndrome in obesityDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Combination drug treatment in obese diabetic patientsEthnic disparities in metabolic syndrome in malaysia: an analysis by risk factors.Immunological response in alcoholic liver disease.Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in miceMetabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study.Matrix metalloproteinases and diabetic vascular complications.A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.Hyperglycemia, lipoprotein glycation, and vascular disease.Metabolic syndrome--cardiovascular disease risk and more.Statins: another class of antihypertensive agents?Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?Rationale for multiple risk intervention: the need to move from theory to practice.The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease.Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice.Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes.Reference genes for real-time PCR quantification of messenger RNAs and microRNAs in mouse model of obesity.The anti-obesity effects of green tea in human intervention and basic molecular studies.Exploring the components of metabolic syndrome with respect to gender difference and its relationship to health-promoting lifestyle behaviour: a study in Taiwanese urban communities.Lipid profile of children with a family history of coronary heart disease or hyperlipidemia: 9-year experience of an outpatient clinic for the prevention of cardiovascular diseases.Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome.Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.The glucose tolerance test, but not HbA(1c), remains the gold standard in identifying unrecognized diabetes mellitus and impaired glucose tolerance in hypertensive subjects.Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study.Interactions among habitual physical activity, eating patterns, and diet composition.A Pre-Exercise Dose of Melatonin Can Alter Substrate Use During Exercise.Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation.Ficus carica leaf extract modulates the lipid profile of rats fed with a high-fat diet through an increase of HDL-C.Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease.Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects.Decreased bodyweight without rebound and regulated lipoprotein metabolism by gymnemate in genetic multifactor syndrome animal.
P2860
Q24814568-ADFA61DD-8831-489D-BA9D-0D7D78CE8ED8Q27687558-DFB98985-7B20-4A44-B134-97B9BA6F7A59Q28192856-3D54703D-4A24-40CB-8046-5A7089676557Q28222549-1FC0380C-D296-4ECE-A02F-60CA60377ECDQ34877652-4A8E884E-3455-40AF-A519-BEE4DD879B0BQ35575752-DC4524F1-D68C-4CDF-8A46-5053EBAA223EQ35615727-EF6394EC-CFB3-4AF9-A8A3-0C41F2DFCD4EQ35626493-0BF8FAAD-CD5F-4197-A96B-5C07FB9AC988Q35638342-737BE4F1-44C0-45F1-9DD4-EFB134F1D8F0Q36081593-379CD829-D3BA-4417-9866-60BE10B21DF5Q36172470-619C51AB-76FF-4AD3-B48E-74C12F762E81Q36218217-565D5AFF-8F71-43C3-B4C1-C3154B06D25EQ36286264-27391D22-36DB-4B18-B997-7B595B4BC07CQ36411099-6C033281-697C-456C-AEBC-ACA4C712B6C9Q36561556-A52DBB8D-FE15-4945-8868-CAF3A71A36A2Q36596889-92D32670-9F72-4960-816F-40AABF82C0F8Q36606602-CAADBE24-56C2-45CD-83A1-BD28F927D21FQ36675450-E7098166-D1B8-4FED-B4C0-307796B4B05DQ36709546-4E3C4AC6-82D7-406A-97EF-4174128CFCF5Q36982540-F641807F-E7F2-4AC6-9A3E-6D98BE046C8CQ37166046-F66810D8-0317-45B8-AE5F-60DC1FE72665Q37490833-2A881937-8765-470D-AC25-DDA32D913160Q38235202-CCAE547E-F721-4456-9279-1238A530C9B1Q39957241-3BEA8227-EC61-43E4-AE7E-A5629A7254F5Q40399875-42542A67-C7EA-4D81-86C9-2C1F4E6AEFF5Q42956394-31D08005-E464-47B8-8977-B3DDEFDF1B96Q43282311-27C920E3-E3A5-445D-9661-B130A8CDC8D7Q46727393-DB7F228D-3297-4F5E-8B55-D379A42A3169Q46804069-9A82A559-01D0-481A-A52A-FA4F226C7355Q46976523-8AC80FFF-8260-46F2-9057-59D872319D9AQ47093897-61E7166B-D232-454D-B2B9-26699993DE60Q47297790-4C47F6B6-A8B9-4BA8-BE4F-ABEED4A975A5Q51054025-E08C2433-B53C-4B08-869F-D30ABBA98CFCQ51366717-D1DCAC75-C787-411C-9E06-94F7DAF7627FQ51475958-33EC9E46-D59D-4739-B3A1-24A3332B96DBQ51905705-F0C12D18-95D2-41E1-B060-24E005CA0019Q53239485-5BA3684F-5730-47CD-A838-C278E2AA9269Q53623239-CAB66B97-4A6E-4D12-B366-913C14B0B939
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Prevention and treatment of the metabolic syndrome.
@ast
Prevention and treatment of the metabolic syndrome.
@en
type
label
Prevention and treatment of the metabolic syndrome.
@ast
Prevention and treatment of the metabolic syndrome.
@en
prefLabel
Prevention and treatment of the metabolic syndrome.
@ast
Prevention and treatment of the metabolic syndrome.
@en
P2860
P1433
P1476
Prevention and treatment of the metabolic syndrome
@en
P2093
D P Mikhailidis
S S Daskalopoulou
P2860
P304
P356
10.1177/00033197040550I601
P50
P577
2004-11-01T00:00:00Z